Back to results
US 2022/0073602 A1Published application
Antibodies with improved stability to intestinal digestion
AssigneeCircle33 LLC
InventorRandall Edward Burton
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeCircle33 LLC
InventorRandall Edward Burton
Estimating the term…
The present invention provides for recombinant antibodies having the features of ruminant early colostrum antibodies that impart resistance to proteases and intestinal digestion. It is a feature of the present invention that when administered to animals including humans, pharmaceutical compositions comprising the novel recombinant antibodies of the present invention, advantageously exhibit resistance to proteases and intestinal digestion. Thus, pharmaceutical compositions of the recombinant antibodies of the invention may be used to deliver antibody therapeutics particularly by oral delivery to the gastrointestinal tract when oral delivery is advantageous.
An isolated recombinant monoclonal antibody comprising (a) heavy and light chain CDRs from a non-bovine antibody and (b) a constant region comprising all or a portion of a bovine IgG1 constant region.
(canceled)
(canceled)
(canceled)
(canceled)
An isolated recombinant monoclonal human antibody, wherein the constant region of the antibody comprises one or more of the following features found in bovine IgG1:
A recombinant fully bovine monoclonal IgG1 antibody.
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.